Скачать или смотреть Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q1 FY25 Results

"Biocon has reported consolidated revenues of Rs 4,567 crore for Q1FY25, showcasing a strong 30% YoY growth, with EBITDA growing 117% to Rs 1,755 crore and a Net Profit of Rs 660 crore.

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

The underlying business performance of Biocon has been in line with our expectations. Post integration, the Biosimilars business has delivered a healthy performance with 19% like- for- like quarterly growth, as it consolidates business across global markets.

This has helped offset the challenges of pricing pressures in the Generics segment and the difficult U.S. Biotech funding environment, which has impacted the growth trajectory of our Research Services business." Kiran Mazumdar Shaw